',6&/2685(
5('$&7('67$7,67,&$/$1$/<6,63/$1
&&8&
$3+$6(5$1'20,=('3/$&(%2&21752//('08/7,&(17(5678'<72 
,19(67,*$7(7+(()),&$&<$1'6$)(7<2)$35(0,/$67&&)2 5
75($70(172)68%-(&76:,7+$&7,9(8/&(5$7,9(&2/,7,6

7KHLQIRUPDWLRQFRQWDLQHGLQWKHDWWDFKHGUHSRUWLVWKHSURSHUW \RI&HOJHQHDQGVKRXOGQRWEHVKDUHGRU
XVHGIRUDQ\SXUSRVHRWKHUWKDQWKDWIRUZKLFKLWZDVSURYLGHG 
&HOJHQHLVFRPPLWWHGWRSURYLGLQJLQIRUPDWLRQDERXWLWVFOLQLFD OWULDOVWRUHVHDUFKHUVDQGSDWLHQWVZLWKWKH
JRDORIIXUWKHULQJVFLHQFHDQGHQKDQFLQJKHDOWKFDUHZRUOGZLGH /DZVDQGUHJXODWLRQVUHTXLUHKRZHYHU
WKDW&HOJHQHSURWHFWVSDWLHQWSULYDF\7KHFRPSDQ\PD\IXUWKHU KDYHOHJDORUFRQWUDFWXDOREOLJDWLRQVQRW
WRGLVFORVHFRPPHUFLDORUWHFKQLFDOLQIRUPDWLRQSURYLGHGE\RU UHODWHGWRFHUWDLQSDUWQHUFRPSDQLHVRU
YHQGRUV
7KHDWWDFKHGUHSRUWLVSUHVHQWHGLQLWVRULJLQDOIRUPDWEXWFH UWDLQLQIRUPDWLRQKDVEHHQUHGDFWHGLQRUGHU
WRFRPSO\ZLWKWKHDIRUHPHQWLRQHGREOLJDWLRQVRUWRSURWHFW&HO JHQH¬∂VFRQILGHQWLDOFRPPHUFLDO
LQIRUPDWLRQ7KHUHGDFWLRQVDUHEDVHGRQWKHIROORZLQJSULQFLS OHV

x5HGDFWHGLQIRUPDWLRQKDVEHHQUHSODFHGE\JUH\VSDFHPDLQWDLQL QJRULJLQDOVSDFLQJDQGSDJLQDWLRQ
x$Q\LQIRUPDWLRQWKDWPLJKWDOORZWKHLGHQWLILFDWLRQRILQGLYLGX DOVKDVEHHQUHGDFWHGIRU
DQRQ\PL]DWLRQ
x$WWDFKPHQWVWRWKLVUHSRUWWKDWFRQWDLQFRQILGHQWLDOLQIRUPDWLR QDUHQRWPDGHDYDLODEOH6XFK
DWWDFKPHQWVLQFOXGHWKRVHWKDWFRQWDLQLGHQWLILDEOHSDWLHQWLQI RUPDWLRQVXFKDVVXEMHFWOLVWLQJV
QDUUDWLYHVDQGSURILOHV7KH\DOVRPD\FRQWDLQFRQILGHQWLDOF RPPHUFLDOLQIRUPDWLRQVXFKDV
PHWKRGRORJLHVDQGK\SRWKHVLVJHQHUDWLQJDQGH[SORUDWRU\DQDO\V HV
x&URVVUHIHUHQFHVWRWKHVHDWWDFKPHQWVVXFKDVOLQNVWRVXEMHFW OLVWLQJVLQ6HFWLRQDUHQRW
UHGDFWHGIURPWKHERG\RIWKHUHSRUW+RZHYHUWKHK\SHUOLQNV LQWKHHOHFWURQLFGRFXPHQWDUHQR
ORQJHUIXQFWLRQDO
x,QIRUPDWLRQDERXW&HOJHQHYHQGRUVDQGWKHLUVHUYLFHVDUHUHGDFW HGEHFDXVHPDQ\FRQWUDFWVSURKLELW
GLVFORVXUHRIWKDWLQIRUPDWLRQ)XUWKHUODZVDQGUHJXODWLRQV SUHYHQWXVIURPGLVFORVLQJFHUWDLQ
LQIRUPDWLRQDERXWRXUYHQGRUVRUWKHLUVHUYLFHVEHFDXVHLWLVS URWHFWHGE\FRS\ULJKW

,QIRUPDWLRQDERXW&HOJHQH¬∂VUHGDFWLRQSROLFLHVDQGWKHDYDLODEL OLW\RIDGGLWLRQDOGDWDIURPWKLVUHSRUWPD\
EHIRXQGDWKWWSZZZFHOJHQHFRPUHVHDUFKGHYHORSPHQWFOLQLFD OWULDOVFOLQLFDOWULDOVGDWDVKDULQJ

&(/*(1(35235,(7$5<,1)250$7,212
55
HVKDUHGRUVKDUHGRU
DQGSDWLHQWDQGSDWLHQW
WLRQVUHTXLULRQVUHTXLU
FRQWUDFWXDORQWUDFWX
HUWDLQSDUWQHUWDLQSDUWQH
QIRUPDWLRQKQIRUPDWLRQ
JHQH¬∂VFRQILQH¬∂VFRQ
LSOHVOHV
DFHPDLQWDLDFHPDLQWD
RQRILQGLYRQRILQG
QILGHQILGHQWLDOLQIWLDOLQ
GHQWLILDEOGHQWLILDEO HS
PD\FRQWDLPD\FRQW Q
QHUDWLQJDQUDWLQJDQ
KPHQWVVXFKPHQWVVXF
KHUHSRUW+KHUHSRUW+
OJHQHYHQGRJHQHYHQG
QIRUPDWLRQQIRUPDWLRQ
XWRXUYHQGRXWRXUYHQG
ERXW&HOJHQERXW&HOJHQ
KWWSZZZKWWSZZZ
Apremilast (CC-10004)
Statistical Analysis Plan. Protocol CC- 10004-UC-001 Celgene 
Confidential and Propri etary 1STATISTICAL ANALYSIS PLAN
$3+$6(5$1'20,=('3/$&(%2 &21752//(' 08/7,&(17(5678'<72
,19(67,*$7(7+( ()),&$&<$1'6$)(7<2)$35(0,/$67&&
)2575($70(172)68%-(&76:,7+$&7,9(8/&(5$7,9(&2/,7,6
STUDY DRUG: $SUHPLODVW
PROTOCOL NUMBER: &&8&
DATE FINAL: 29 Sep 2017
Prepared by:
on behalf of
Celgene Corporation
86 Morris Avenue
Summit, NJ 07901
CONFIDENTIAL
The information contained in this document is regarded as confidential 
and, except to the extent necessary to obtain informed consent, may not be 
disclosed to another party unless such disclosure is required by law or 
regulations.  Persons to whom the information is disclosed must be 
informed that the information is confidential and may not be further 
disclosed by them.&(/*(1(35235,(7$5<,1)250$7,21rporatiporati onon
rris Avenurris Avenu
ummit, NJ ummit, NJ 
The infThe inf
and, nd, 1(1
(/(/
Apremilast (CC-10004)
Statistical Analysis Plan. Protocol CC- 10004-UC-001 Celgene 
Confidential and Propri etary 2TABLE OF CONTENTS
SIGNATURE PAGE ...................................................................................................................6
1. LIST OF ABBREVIATIONS ...................................................................................8
2. INTRODUCTI ON..................................................................................................10
3. STUDY OBJECT IVES ...........................................................................................11
3.1. Primary Objective ...................................................................................................11
3.2. Secondary Ob jectives .............................................................................................11
 
4. INVESTIGATIONAL PLAN .................................................................................13
4.1. Overall Study Desi gn and Pl an ...............................................................................13
4.2. Study Endpoints .....................................................................................................15
4.2.1. Primary Endpoint ....................................................................................................15
4.2.2. Secondary Efficacy  Endpoint s ................................................................................15
4.2.3. Secondary Safety Endpoints ...................................................................................16
4.3. Stratification, Randomization, and Blinding ............................................................17
4.4. Sample Size Deter mination .....................................................................................17
5. GENERAL STATISTICA L CONSIDERA TIONS .................................................18
5.1. Reporting Conventions ...........................................................................................18
5.2. Safety Analysi s Periods ..........................................................................................18
5.3. Time Points ............................................................................................................20
5.3.1. Analysis Time Point Assignments ...........................................................................20
5.3.2. Screening and Baseline Definitions .........................................................................21
5.4. Analysis Populations ..............................................................................................21
5.4.1. Intent-to-treat Population ........................................................................................21
5.4.2. Per-protocol Population ..........................................................................................21
5.4.3. Safety Population....................................................................................................22
5.4.4. Apremilast Subjects as Randomized Population ......................................................22
5.4.5. Apremilast Subjects as Treated Population .............................................................22
6. SUBJECT DI SPOSITION ......................................................................................23&(/*(1(35235,(and Blindinnd Blindi
...................
CAL ACONCON
ioonsns.............
is PeriodsPeriods
tss.............
sis Time Pois Time Po
creening aneening a
AnalysisAnalysis
Inntentennn
4.2. P4.2. P
5.4.3..4(7$5<,1)25..........................
....................
.....................
.................. ..
.......................
.................. .........50$7,2111
.......1111
0$50250
(7$5,(7
Apremilast (CC-10004)
Statistical Analysis Plan. Protocol CC- 10004-UC-001 Celgene 
Confidential and Propri etary 37. PROTOCOL DEVIATIONS/VIOLATIONS ..........................................................24
8. DEMOGRAPHICS AND BASELI NE CHARACTERISTICS ................................25
8.1. Demographics and Bas eline Character istics ............................................................25
8.2. Baseline Disease Cha racteristics.............................................................................25
8.3. Medical Hist ory......................................................................................................27
8.4. Prior Medications /Procedure s .................................................................................27
9. EXTENT OF EXPOSURE TO INVESTIGATIONAL PRODUCT .........................28
9.1. Treatment Duratio n.................................................................................................28
9.2. Treatment Compliance ............................................................................................28
10. CONCOMITANT MEDICATIONS AND PROCEDURES ....................................30
10.1. Concomitant Medications .......................................................................................30
10.2. Concomitant Pro cedures .........................................................................................30
11. EFFICACY ANALYSIS ........................................................................................31
11.1. Multiplici ty.............................................................................................................3 1
11.2. Missing Data Handling ...........................................................................................31
11.2.1. Treatment Failures ..................................................................................................31
11.2.2. Binary Efficacy Endpoints ......................................................................................31
11.2.2.1. Primary Approach for Analysis ...............................................................................31
11.2.2.2. Sensitivity Analyses ...............................................................................................32
11.2.2.3. Approach for Descriptive Summary ........................................................................32
11.2.3. Continuous Efficacy Endpoints ...............................................................................32
11.2.3.1. Primary Approach for Analysis ...............................................................................32
11.2.3.2. Approach for Descriptive Summary ........................................................................32
11.3. Analysis of Primar y Endpoint .................................................................................32
11.3.1. Primary Analysis of  Primary Endpoint ....................................................................32
11.3.2. Sensitivity Analyses of Primary Endpoint ...............................................................33
11.4. Analyses of Secondary Efficacy E ndpoints .............................................................33
&(/*(1(35235,(7$5<,1)250$7,2177
.......282
..............28.2
.........................
..........................
..........................
..........................
..........................
..................
.........................
..........................
.........................
........................
.......................
SummarySummary
EndpoEndpo inttss
h for Analyh for Analy
DescriptDescrip iv
of Primaryof Primar
ary Analysiary Analysi
ensitnsitivitivity yAA
AnalyseAnalyse
/*
&(/
&
Apremilast (CC-10004)
Statistical Analysis Plan. Protocol CC- 10004-UC-001 Celgene 
Confidential and Propri etary 411.7. Assessing Study Center Effect a nd Treatment-by-center  Interacti on .......................36
12. SAFETY ANALYSIS ............................................................................................37
12.1. Adverse Ev ents.......................................................................................................37
12.1.1. Overall Summary of TEAEs ...................................................................................37
12.1.2. All TEAEs ..............................................................................................................3 8
12.1.3. Common TEA Es ....................................................................................................38
12.1.4. Drug-related TEAEs ...............................................................................................39
12.1.5. TEAEs by Maximu m Severi ty ................................................................................39
12.1.6. Se rious TEAEs .......................................................................................................39
12.1.7. TEAEs Leading to Drug Interruption and Leading to Drug Withdrawal ..................39
12.1.8. Deaths ....................................................................................................................39
12.2. Clinical Laboratory Evaluations..............................................................................40
12.3. Vital Signs and Body Wei ght..................................................................................40
12.4. Electrocardi ogram ..................................................................................................41
15. CHANGES TO THE STATISTICAL ANALYSES SECTION OF THE 
PROTOCOL...........................................................................................................46
16. REFERENCES.......................................................................................................47
17. APPENDICES ........................................................................................................48
17.1. Laboratory Marked Abnorm alities Criteria .............................................................48
&(/*(1(35235,(7AL ANALL ANAL
.......................
...........................
.......................
AbnormAbnorm alal7$5<,1)250$7,2188
.......383
..............393
.........................
..........................
hdrawalhdrawal ....
..........................
..........................
..................
.........................
7$5(7$
35
Apremilast (CC-10004)
Statistical Analysis Plan. Protocol CC- 10004-UC-001 Celgene 
Confidential and Propri etary 5LIST OF TABLES
Table 1: Abbreviations and Specialist Terms ..........................................................................8
Table 2: Definitions of Entry and Completion in Disposition Summaries ..............................23
 
Table 5: Laboratory Marked A bnormalities Cr iteria .............................................................48
LIST OF FIGURES
Figure 1: Overall Study Design ..............................................................................................15
&(/*(1(35235,(7$5<,1)25.....................50$.................... 440$7,217
0$7
250
0$7
(1(35235,
Apremilast (CC-10004)
Statistical Analysis Plan. Protocol CC- 10004-UC-001 Celgene 
Confidential and Propri etary 81. LIST OF ABBREVIATIONS
Table 1: Abbreviations and Specialist Terms
Abbreviation Meaning
AE Adverse event
ANCOVA Analysis of covariance
APR 30 BID, 
APR 40 BIDApremilast 30 mg twice daily,
Apremilast 40 mg twice daily
BID Twice daily
BMI Body mass index
CI Confidence interval
CMH Cochran-Mantel-Haenszel
CRF Case Report Form
ECG Electrocardiograms
GI Gastrointestinal
HRQoL Health-related quality of life
IP Investigational product
ITT Intent-to-treat
IVRS Interactive Voice Response System
IWRS Interactive Web Response System
MedDRA Medical Dictionary for Regulatory Activities
MMS Modified Mayo score
 
PGA Physician‚Äôs global assessment
PMS Partial Mayo score&(PGAPGA&(/*(1(3523roductrodu23atat52
ctive Voice ctive Voi35
nteractive Weractive W(
MedicalMedical1((MoMo*(*(*(*(/****
(/35,(7$5<,1)250$7,21$7$7$7$70$502
1),1<5<
7$(7fefe5,(35
&(&235
&
Apremilast (CC-10004)
Statistical Analysis Plan. Protocol CC- 10004-UC-001 Celgene 
Confidential and Propri etary 9Abbreviation Meaning
PP Per-protocol
PT Preferred term
RBS Rectal bleeding subscore
SAE Serious adverse event
SAP Statistical analysis plan
SF-12v2 The Medical Outcomes Study Short Form 12-item Health Survey, version 2 (SF-
12v2)
SFS Stool frequency subscore
SOC System organ class
SD Standard deviation
TEAE Treatment- emergent adverse event
TMS Total Mayo score
UC Ulcerative colitis
WHO World Health Organization 
&(/*(1(35235,(7$5<,1)250$7,21777$72 (SFSF-$7$7$7
5025)21)
<,5<$57$
Apremilast (CC-10004)
Statistical Analysis Plan. Protocol CC- 10004-UC-001 Celgene 
Confidential and Propri etary 102. INTRODUCTION
This statistical analysis plan (SAP) describes the analyses and data presentations for Celgene‚Äôs 
protocol CC-10004-UC-001 ‚ÄúA Phas e 2, Randomized, Placebo-Controlled, Multicenter Study to 
Investigate the Efficacy and Safety of Apremilast (CC-10004) for Treatment of Subjects with 
Active Ulcerative Colitis‚Äù as amended on 20 Ju l 2016. It contains definitions of analysis
populations, deri ved variables and statist ical methods for the analysis of efficacy and safety.  
 
Planned data analyses include 1) an analysis at the completion of the 12-week Placebo-controlled 
Phase for all subjects (referred to as the Double-blind Placebo-controlled Phase analysis hereafter), 2) an analysis at the completion of  the Active-treatment Phase (through Week 52) for 
all sub jects, and 3) the final analysis at the completion of the entire study.
In this SAP, apremilast 30 mg twice daily (BID) and apremilast 40 mg BID are referred to as 
APR 30 BID and APR 40 BID, re spectively. Investigatio nal product (IP) refers to placebo, APR 
30 BID, or APR 40 BID.
&(/*(1(35235,(7$5<,1)250$7,21eboebo-controcontro
analysis analysis
rough Weerough Wee
g BID are rg BID are r
ct (IP) referct (IP) ref7$0$50$
Apremilast (CC-10004)
Statistical Analysis Plan. Protocol CC- 10004-UC-001 Celgene 
Confidential and Propri etary 113. STUDY OBJECTIVES
3.1. Primary Objective
The primary objective of the study is to evaluate the clinical efficacy of apremilast (30 mg BID
and 40 mg BID), compared with placebo, in s ubjects with active ulcerative colitis (UC).
3.2. Secondary Objectives
The secondary objectives of the study are:
!To evaluate the safety and tolerability of apremilast (30 mg BID and 40 mg BID), 
compared with placebo, in subjects with active UC
!To evaluate the long-term safety in subjects with active UC, receiving apremilast (30 mg 
BID or 40 mg BID)
 
 
 
 
&(/*(1(35235,(7$5<,1)250$7,21g BID), BID), 
ng apremilang apremil
$5<7$(7$5,(735235235(31(1(*(1/(/*&(/&(&(
Apremilast (CC-10004)
Statistical Analysis Plan. Protocol CC- 10004-UC-001 Celgene 
Confidential and Propri etary 12 
 
&(/*(1(35235,(7$5<,1)250$7,21
Apremilast (CC-10004)
Statistical Analysis Plan. Protocol CC- 10004-UC-001 Celgene 
Confidential and Propri etary 134. INVESTIGATIONAL PLAN
4.1. Overall Study Design and Plan
This is a Phase 2, multicenter, randomized, double-blind, placebo-controlled, parallel-group, 
study to evaluate the efficacy and safety of 2 doses of apremilast in subjects with active UC 
(defined as a total Mayo score [TMS] of ‚â• 6 to ‚â§ 11, with an endoscopic subscore ‚â• 2).
Approximately 165 subjects (55 subjects per arm) will be randomized in a 1:1:1 ratio using an 
Interactive Voice Response system (IVRS) or an Interactive Web Response System (IWRS) to receive oral apremilast (30 mg BID or 40 mg BID), or identically appearing placebo BID for up 
to 12 weeks, followed by 40 weeks of blinded treatment with apremilast (30 mg BID or 40 mg 
BID). At the end of 52 weeks in the study, subjects who have a Mayo endoscopy score ‚â§ 1 will 
have the opportunity to participate in the Extension Phase and will continue to receive the same 
treatment assigned during the Blinded Active-treatment Phase for an additional 52 weeks.
Treatment assignment will be stratified via IVRS/IWRS based on concomitant use of oral 
corticosteroids and previous exposure to immunosuppressants (eg, 6-MP, AZA, or MTX). The 
number of subjects with previous exposure to immunosuppressants is targeted to comprise, no 
more than 50% of the subjects enrolled, and no less than 30%. 
The study will consist of 5 phases:
!Screening Phase ‚Äì up to 4 weeks
!Double-blind Placebo-controlled Phase ‚Äì Weeks 0 to 12
!Blinded Active-treatmen t Phase ‚Äì Weeks 12 to 52
!Extension Phase ‚Äì Weeks 52 to 104
oThe 52-week extension is a blinded, active treatment phase and henceforth will be 
referred to as the Extension Phase for the remainder of the document.
!Post-treatment Observational Follow-up Phase ‚Äì T he 4-week period after the last dose of 
investigational product (IP).
Double-blind Placebo-controlled Phase
Eligible subjects will enter the Double-blind Placebo-controlled Phase for 12 weeks, at the 
Baseline Visit (Week 0, Visit 2). Subjects will be  randomly assigned to study treatment as 
described above. With the aim to mitigate potenti al dose-related side effects associated with 
apremilast, such as headache and gastrointestinal (GI) disturbances, apremilast-treated subjects 
will be dose-titrated in 10-mg/day increments over the first 8 days of treatment. All subjects will 
receive blister cards of identi cal appearance to maintain bli nding. Subjects will continue to 
receive the treatment assigned at baseline for 12 weeks.
Blinded Active-treatment Phase
Following 12 weeks of treatment, subjects will en ter the Blinded Active-treatment Phase for 40 
weeks. At the Week 12 visit, subjects will be evaluated for clinical improvement based on the &(/*(1(35235,(7$5<,1)250$7,21g an g an 
WRS) to WRS) to 
BID for upBID for up
BID or 40 mD or 40 m
py score y score ‚â§ ‚â§
to receive to receive
titionalonal 52 w5ll
ncomitant ucomitant 
, 66-MP, AZP, AZ
antsntsis targis
%. %. 
‚ÄìWeeks 0 Weeks 
Weeks 12 Weeks 12 tot
104104
sion is a blin is a bli
ExtensioExtensio nn
rvational Frvational
roduct (IP)roduct (IP
boo--controlcontro
s will enter s will enter
t (Week 0,t (Week 0,
above. Witbove. Wit
last, such aast, such a
be dosebe dose --tititrtiii
ceive blisteceive blist
receive theceive th
nd
Apremilast (CC-10004)
Statistical Analysis Plan. Protocol CC- 10004-UC-001 Celgene 
Confidential and Propri etary 14TMS. The endoscopy subscore assessed by the investigator will be used for the calculation of the 
Week 12 TMS. 
Subjects who achieve at least a 20% decrease from baseline in the TMS at Week 12 will receive 
the following IP between the Week 12 Visit and the Week 52 Visit:
!Subjects who were randomized to apremilast (30 mg BID or 40 mg BID) at baseline will 
continue to receive the treatment assigned at baseline.  
!Subjects who were randomized to placebo at baseline will be re-randomized to receive 
apremilast (30 mg BID or 40 mg BID) and will be dose-titrated in 10-mg/day increments over the first 8 days of treatment.  
Subjects who do not achieve at least a 20% decreas e from baseline in th e TMS at Week  12 will 
receive the following IP until the Week 52 Visit:
!Subjects who were randomized to apremilast 30 mg BID at baseline will be re-assigned 
apremilast 40 mg BID, with no dose titration.
!Subjects who were randomized to apremilast 40 mg BID at baseline will continue to 
receive apremilast 40 mg BID.
!Subjects who were randomized to placebo at baseline will be re-randomized to receive 
apremilast (30 mg BID or 40 mg BID) and will be dose-titrated in 10-mg/day increments over the first 8 days of treatment.
In order to maintain the blind for the treatment assigned at baseline, all subjects will receive 
blister cards of identical appearance during the titration period beginning at Week 12. However, for subjects continuing on the dosage of apremilast assigned at baseline, and for subjects who are 
not undergoing dose titration (as noted above), the IP included in the ‚Äútitration‚Äù portion of the 
blister card will include the total daily dose of apremilast (30 or 40 mg BID) and will not include the dose titration .
Extension Phase
At the end of the Blinded Active-treatment Phase (Week 52), subjects who have a Mayo 
endoscopy score ‚â§ 1 will have the opportunity to participate in the Extension Phase. Subjects 
participating in the Extension Phase will cont inue to receive the same treatment assigned during 
the Blinded Active-treatment Phase for an additional 52 weeks (ie, Weeks 52 to 104).
Post-treatment Observational Follow-up Phase
All subjects are required to spend 4 weeks in the Post-treatment Observational Follow-up Phase 
following the last dose of IP.
The study schematic is presented in Figure 1 below.
&(/*(1(35235,(7$5<,1)250$7,21ments ents 
eek 12eek 12 will will
will be reill be re -asas
eline will celine will 
will be rell be -ran
oseose-tititrated tratediii
ned at baseled at basel
aatition perion per o
last assigneast assign
e), the IP ine), the IP in
se of apremse of aprem
vee--treatmtreatm en
ave the oppve the op
nsiosin PhasePh
eatmatment Phent P
ObservatioObservatio
are requiredare required
he he last dosast dos
udyudyschemschemyy
Apremilast (CC-10004)
Statistical Analysis Plan. Protocol CC- 10004-UC-001 Celgene 
Confidential and Propri etary 15Figure 1: Overall Study Design
4.2. Study Endpoints
4.2.1. Primary Endpoint
The primary endpoint of this study is the proporti on of subjects achieving a clinical remission in
the TMS at Week 12, defined as a TMS of ‚â§ 2, with no individual subscore > 1.
4.2.2. Secondary Efficacy Endpoints
!The proportion of subjects achieving clinical response at Week 12, defined as a decrease 
from baseline in the TMS of at least 3 points and at least 30%, along with a reduction in the rectal bleeding subscore (RBS) of at least 1 point or an absolute RBS of ‚â§ 1
!The proportion of subjects achieving endosc opic remission at Week 12, defined as a 
Mayo endoscopic subscore of 0
!The proportion of subjects achieving endoscopic response at Week 12, defined as a 
decrease from baseline of at least 1 point  in the Mayo endoscopic subscore
!The proportion of subjects achieving a RBS ‚â§ 1 at Week 12
!The proportion of subjects achieving clinical remi ssion in the modified Mayo Score 
(MMS) (range: 0 to 9, based on stool frequency (SFS), RBS and endoscopy) at Week 12, 
defined as a score of 2 points or lower, with no individual subscore exceeding 1 point
!The proportion of subjects achieving clinical response in the MMS at Week 12, defined 
as a decrease from baseline at least 2 points and at least 25%, along with a reduction in the RBS of at least 1 point or an absolute RBS of ‚â§ 1 point&(/*(1(35235,(7$5<,1)250$7,21
proportiproporti on on
S of of ‚â§ 2, wi‚â§ 2, w
EndpointsEndpoints
jects achievjects achie
e TMS of aTMS of a
ng subscorng subsco
tion ofn of subj subjff
doscopidoscopi c sucs
proportiproporti on on
ecrease froease fro
The propThe pro
!!TheThe
(
Apremilast (CC-10004)
Statistical Analysis Plan. Protocol CC- 10004-UC-001 Celgene 
Confidential and Propri etary 16!The proportion of subjects achieving clinical r emission at Week 8, defi ned as a partial 
Mayo score (PMS) of ‚â§ 2, with no individual subscore > 1
!The proportion of subjects achieving clinical response at Week 8, defined as a decrease 
from baseline in the PMS of at least 2 points and at least 25%, along with a reduction in 
the RBS of at least 1 point or an absolute RBS of ‚â§ 1 point
4.2.3. Secondary Safety Endpoints
!Type, frequency, severity, and relationship of AEs to IP
!Number of subjects who discontinue IP due to any AE
!Frequency of clinically significant changes in physical examination, vital signs, and/or 
laboratory findings
 
 
 
 
 
 
 
 
 
&(/*(1(35235,(7$5<,1)250$7,21ns, and/or ns, and/or 
1)2
<, 1
$5<7$5(7$
35,23552335235(31((1(*(1/*(((/*&(/&
Apremilast (CC-10004)
Statistical Analysis Plan. Protocol CC- 10004-UC-001 Celgene 
Confidential and Propri etary 17 
 
 
4.3. Stratification, Randomization, and Blinding
Approximately 165 subjects (55 subjects per arm) will be randomized in a 1:1:1 ratio using an 
IVRS/IWRS to receive oral apremilast (30 mg BID or 40 mg BID), or identically appearing placebo BID for up to 12 weeks, followed by 40 weeks of blinded treatment with apremilast (30 
mg BID or 40 mg BID).  At the end of 52 weeks in the study, subjects who have a Mayo 
endoscopy score ‚â§ 1 will have the opportunity to participate in the Extension Phase and will 
continue to receive the same treatment assigned during the Blinded Active-treatment Phase for 
an additional 52 weeks.
Treatment assignment will be stratified via IVRS/IWRS based on concomitant use of oral 
corticosteroids and previous exposure to immunosuppressants (eg, 6-MP, AZA, or MTX).  The 
number of subjects with previous exposure to immunosuppressants is targeted to comprise, no 
more than 50% of the subjects enrolled, and no less than 30%.
4.4. Sample Size Determination
A 2-group chi-square test with a 0.1 two-sided significance level will have approximately 80%
power to detect a true 20% absolute difference (30% versus 10%) between a dose of apremilast
and placebo, for the proportion of subjects achieving a clinical remission at Week 12 when thesample size in each group is 49. Assuming a dropout rate of 10% prior to Week 12, 
approximately 165 subjects (approximately 55 subjects per group) are planned to be randomized
in this study.
&(/*(1(35235,(7$5<,1)ndomized indomized 
mg BID), omg BID), o
of blindedof blinded
the studyhe study , s,
partiparticipate cipate
d durid duri ng thng th
via IVRS/Ivia IVRS
re to immune to imm
exposure texposure
enronrolled, alled, a
ze Determe Deter
e test with atest with
true 20% atrue 20% a
or the propor the pro
in each groin each gro
matelyely 165 s165y
 studystud .)250$7,21$0$50$502
1)2
Apremilast (CC-10004)
Statistical Analysis Plan. Protocol CC- 10004-UC-001 Celgene 
Confidential and Propri etary 185. GENERAL STATISTICAL CONSIDERATIONS
5.1. Reporting Conventions
The following reporting conventions apply ge nerally to tables, listings, and figures:
!Treatment comparisons between each apremilast group and the placebo group will be 
made for the efficacy  analyses.
!Stratified analyses will use the 2 rando mization str atification factors (concomitant use of 
oral corticosteroids [yes/no] and previous exposure to immunosuppressants [yes/no]), unless otherwise specified.
!Stratified analyses and subgroup analyses with respect to the 2 randomization 
stratification factors will be based on each subject‚Äôs actual st rata according to the clinical 
database of prior/concomitant medications, rather than the strata as randomized in the IVRS/IWRS.
!P-values will be 2-sided and presented with 4 decimal places. P-values that are rounded 
to 0.0000 will be presented as ‚Äú< 0.0001‚Äù and p-values that are rounded to 1 ‚Äú> 0.9999‚Äù.
!Confidence intervals (CIs) will be presented as 2-sided 95% CIs.
!Summary statistics will consist of the number and percentage of subjects in each category 
for discrete variables, and the sample size, mean, standard deviation (SD), median, minimum, 25
thpercentile (Q1), 75thpercentile (Q3), and maximum for continuous 
variables.
!All mean, median, Q1, Q3, and CI values will be formatted to one more decimal place 
than the measured value. Standard deviation values will be formatted to two more 
decimal places than the measured value. Min imum and maximum will be formatted to the 
same number of decimal places as the measured value.
!All percentages will be rounded to one decimal place. The number and percentage of 
responses will be presented in the form XX (XX.X), where the percentage is in the 
parentheses.
!Change from baseline is calculated as the post-baseline value minus the baseline value.
!All laboratory data will be reported using standard international units.
!All analysis and summary tables will include the analysis population sample size (ie, 
number of subjects) in the column headings.
!Listings will include both the randomized treatment and actual treatment.
5.2. Safety Analysis Periods
For the safety analysis, the following analysis periods for post-baseline data are defined. Safety 
data in these periods are considered treatment-emergent.&(/*(1(35235,(7$5<,1)250$7,21use of use of 
s/no])s/no]) ,
atatioion n 
ording to thrding to th
randomizrandomiz
es. Pes. P -value-valu
hat ahat a re rou
ded 95% CIed 95% CI
nd percentand percent
meanean,s,standaan
ntile (Q3), ntile (Q3)
values wilvalues wil
rd deviatrd deviat ioi
sured valueured valu
placesplaces as ths t
be rounded be rounded 
presenesented inted innnn
m baseline m baseline
oratoryoratory  datday
analysis aanalysis a
number of number of
!!ListListinging
5.2.5.2
Apremilast (CC-10004)
Statistical Analysis Plan. Protocol CC- 10004-UC-001 Celgene 
Confidential and Propri etary 19!Weeks 0-12 placebo-controlled phase: This period encompasses data through Week 12. It 
starts on the date of the first dose of IP in the study, and ends  on the d ate be fore IP 
dispensing at Week 12 for subjects who receive at least 1 dose of IP after Week 12
(defined as the date of the last dose of IP in the study no earlier than the date of IP 
dispensing at Week 12), or 28 days after the last dose of IP in the study or on the date of the actual last follow-up in the study, whichever comes first, for subjects who discontinue 
at or prior to Week 12.
Of note, this period is exclusive of the date of the first dose of IP in the study and 
inclusive of the date of IP dispensing at Week 12 for the analyses of the lab, vital signs, 
weight, and ECG data.
The safety analysis tables for the placebo-controlled phase will be presented by the 
following 4 groups: placebo, APR 30 BID, APR 40 BID, and APR total. 
!Weeks 0-52 apremilast-exposure period: This period encompasses all apremilast-
exposure data through Week 52, irrespective of when the apremilast exposure starts (at Week 0 or 12) in the study. It starts on the date of the first dose of apremilast in the study, 
and ends on the date before IP dispensing at Week 52 for subjects who receive at least 1 
dose of apremilast after Week 52 (define d as the date of the last dose of apremilast in the 
study no earlier than the date of IP dispensing at Week 52), or 28 days after the last dose 
of apremilast in the study or on the date of the actual last follow-up in the study, 
whichever comes first, for subjects who discontinue at or prior to Week 52.
Of note, this period is exclusive of the date of the first dose of apremilast in the study and 
inclusive of the date of IP dispensing at Week 52 for the analyses of the lab, vital signs, 
weight, and ECG data.
The safety analysis tables, with an exception for the summaries of labs, vital signs, and 
body weight by time point, for the apremilas t-exposure period during Weeks 0-52 will be 
presented by the following 4 groups: APR 30 BID, APR 40 BID, APR 30 BID/APR 40 BID, and APR total, as follows:
oThe APR 30 BID group includes the data during the APR 30 BID treatment for 
subjects who receive APR 30 BID only in the study, subjects who initially receive APR 30 BID and switch to APR 40 BID at Week 12, and subjects who initially 
receive placebo and switch to APR 30 BID at Week 12.
oThe APR 40 BID group includes the data during the APR 40 BID treatment for 
subject who receive APR 40 BID only in the study and subjects who initially 
receive placebo and switch to APR 40 BID at Week 12.
oThe APR 30 BID/APR 40 BID group includes the data during the APR 40 BID 
treatment for subjects who initially receive APR 30 BID and switch to APR 40 
BID at Week 12.
oThe APR total group combines all the data of all the groups.
For the summaries of labs, vital signs, and body weight by time point, the data during the 
APR 30 BID and APR 40 BID treatments after Week 12 for subjects who initially receive &(/*(1(35235,(7$5<,1)250$7,21gns, ns, 
by the by the 
apremilastapremilast
st exposuret exposure
of apremilaof aprem
jects ects who who 
e last dose last dose
52), or 28 d52), or
last followlast follow
nue at or priue at or pri
the first dthe first
eek 52 eek 5 for fo
exceptxcept ioion n f
he apremilhe apremi
groups: APgroups: 
ows:ws
ID group inID group i
o receive Areceive A
BID and swBID and s
e placebo ae placebo
he APR 40 he APR 40 
subject whsubject w
receivereceive
oThTh
Apremilast (CC-10004)
Statistical Analysis Plan. Protocol CC- 10004-UC-001 Celgene 
Confidential and Propri etary 20placebo and switch to APR 30 BID and APR 40 BID, respectively, at Week 12 will be 
summarized in the placebo/APR 30 BID and placebo/APR 40 BID groups, respectively.
!Weeks 0-104 apremilast-exposure period: This period encompasses all apremilast-
exposure data through Week 104, irrespective of when the apremilast exposure starts (at Week 0 or 12) in the study. It starts on the date of the first dose of apremilast in the study, and ends 28 days after the last dose of apremilast in the study or on the date of the actual 
last follow-up in the study, whichever comes first.
Of note, this period is exclusive of the date of the first dose of apremilast in the study for 
the analyses of the lab, vital signs, weight, and ECG data.
The treatment groups presented in the safety analysis tables for the apremilast-exposure 
period during Weeks 0-104 will be the same as those for the apremilast-exposure period during Weeks 0-52.
!Weeks 52-104 apremilast-exposure period: This period encompasses the apremilast-
exposure data during Weeks 52-104 and is to be summarized for subjects who receive at least 1 dose of apremilast after Week 52 (define d as the date of the last dose of apremilast
in the study no earlier than the date of IP dispensing at Week 52). It starts on the date of 
IP dispensing at Week 52, and ends 28 days after the last dose of apremilast in the study or on the date of the actual last follow-up in  the study, whichever comes first.
Of note, this period is exclusive of the d ate of IP dispensing at Week 52 for the analyses 
of the lab, vital signs, weight, and ECG data.
The safety analysis tables for the apremilast-exposure period during Weeks 52-104 will 
be presented by the following 3 groups: APR 30 BID, APR 40 BID, and APR total.
In the analyses of the lab, vital signs, weight, and ECG data, the value at the end of an analysis 
period is determined as the last post-baseline value among scheduled, unscheduled, and ET visits 
(excluding the follow-up visit) in the analysis period, whereas the worst value of an analysis 
period is determined among all visits (including the follow-up visit) in the analysis period.
5.3. Time Points
5.3.1. Analysis Time Point Assignments
The designation of time points used for analysis (analysis time points) will be based on the actual 
day of assessment relative to the date of the first dose of IP in the study (r elative day, ie, date of 
assessment ‚Äì date of the first dose of IP in the st udy + 1), rather than the nominal visit recorded.
Visits to be assigned with this method include the screening, Week 0 through Week 104, 
unscheduled, and early termination visits. The only exception is the assessments recorded at the post-treatment observational follow-up visit, wh ich will be assigned to the follow-up visit.
All assessments performed prior to the date of the first dose of IP in the study will be assigned to 
the screening analysis time point. All assessments performed on the date of the first dose of IP in the study will be assigned to the Week 0 analysis time point.
The analysis time point assignments for the post-baseline visits (excluding the post-tr eatment 
observational follow-up visit) will be based on the relative day windows. These relative day 
windows are continuous, mutually exclusive, stretch from the date after the first dose of IP in the &(/*(1(35235,(7$5<,1)250$7,21foor r
exposure xposure 
osure perioosure perio
 the apremthe aprem
subjects ubjects whh
ththe le last doast d
k 52). It stak 52). It 
dose of apdose of ap
whicheverwhichev
dispensing ispensing 
stt--exposureexposure
APR 30 BAPR 30 B
ht, and ECGt, and EC
eline value eline valu
analysis peanalysis
its (includi(includi
me Pointme Point A
time potime po intint
nt nt relatrelative tive
date of thedate of the
e assiassigned gned 
duled, duled, and eand 
treatmtreatm ent oent 
AAll ll assessmassessm
thhe e screecre
st
Apremilast (CC-10004)
Statistical Analysis Plan. Protocol CC- 10004-UC-001 Celgene 
Confidential and Propri etary 21study to the midpoint between the first 2 schedu led visits, from midpoint to midpoint between 
each successive pair of scheduled visits, and from the last midpoint onward for the last scheduled 
visit. If data are available on multiple days with in a relative day window, then the assessment 
closest to the visit‚Äôs target day (ie, study week √ó 7 + 1) will be used for that analysis time point. 
If the relative days from 2 assessments are equally  close to, but on different sides of the target 
day, then the latter assessment will be used for that analysis time point. If multiple assessments 
are available on the same relative day, then the average of these assessments will be used for that relative day, except for the lab and ECG data for which the assessment at a later time of the same 
day will be used.
For efficacy  analyses, the data after the date of treatment failure (Section 11.2) 
will be set to missing prior to the assignments of analysis time points.
5.3.2. Screening and Baseline Definitions
The screening SFS and RBS (involving the subject diary data) w ill be derived from the 3 ear liest 
days with a non-missing value within a 7-day wi ndow that is allowed to be  rolling within the 14 
days of the screening visit, whereas the screening PGA is defined as the first assessment on or 
before the date of the first dose of IP in the study.
Unless otherwise specified, the baseline value is defined as the last assessment on or before the 
date of the first dose of IP in the study. The baseline SFS and RBS will be derived from the 3 
most recent days (or as few as 2 days) with a non-missing value within the 7 days prior to the 
day before the screening endoscopy. In case of  insufficient diary data during this period, the 
baseline value will be set to the screening value. The baseline TMS is calculated using the 
baseline SFS, RBS, PGA, and endoscopy subscores that are identified separately. The baseline PMS and MMS are calculated similarly.
For the safety analysis, the baseline value is de fined as the last assessment on or before the date 
of the first dose of IP in the study for the analy sis of the placebo-controlled phase, and the last 
assessment on or before the date of the first dose of apremilast for the analysis of an apremilast-
exposure period.
5.4. Analysis Populations
5.4.1. Intent-to-treat Population
The intent-to-treat (ITT) population will be the primary population fo r the efficacy analysis. The 
ITT population will consist of all subjects who ar e randomized as specified in the protocol and 
receive at least 1 dose of IP. To assess change from baseline, a baseline value and at least 1 post-
baseline value are also required. Subjects will be included in the treatment group to which they 
were randomized, irrespective of the treatments actually received.
5.4.2. Per-protocol Population
A supportive analysis using the per-protocol (PP) population will be performed for the primary 
efficacy endpoint (clinical remission defined in the TMS) and the first secondary efficacy 
endpoint (clinical response defined in the TMS). The PP population will consist of all subjects 
included in the ITT population who have no protocol  violations that may substantially affect the
efficacy results. These protocol violations coul d include, but are not limited to, not meeting key &(/*(1(35235,(7$5<,1)250$7,21e e 
1.21.2) )
d frod fro m ththe
e rolling we rolling w
e first e first asseass
last ast assessma
RBSRBS will wil
value witvalue wit hh
cient diary dient diary 
e baseline Te baseline
es that arees that are
is defined is defined 
he analysis e analysis
he first doshe first d
ulationulation ss
treat Poputreat Pop
(ITT) pop(ITT) pop
will consiwill con
ast 1 doseast 1 dose
value are aue are a
randomizedandomized
.4.2..4.2.
A suppA supp
Apremilast (CC-10004)
Statistical Analysis Plan. Protocol CC- 10004-UC-001 Celgene 
Confidential and Propri etary 22inclusion/exclusion criteria, gross IP non-compliance, receiving incorrect IP, treatment 
unblinding by the investigator, concomitant use of protocol-prohibited medications that are 
potentially effective for UC fo r an unrelated comorbid condition, not having the required 
assessment at the designated time point for reasons other than experiencing a treatment failure, or discontinuing due to lack of efficacy or a drug -related AE prior to the time point. The final 
determination on protocol violations, and thereby the composition of the PP population, will be 
made prior to the unblinding of the database for  the Double-blind P lacebo-controlled Phase 
analysis and will be separately documented. Subjects will be included in the treatment group to 
which they were rando mized, i rrespective of the treatments actually received.
5.4.3. Safety Population
The safety analysis for the placebo-cont rolled phase will be based on the safety population, 
which will consist of all subjects who are randomized  and receive at least 1 dose of IP. At least 1
post-baseline assessment is required for inclusion in the analysis of each specific laboratory, vital 
sign, weight, or ECG parameter. To assess change from baseline, a baseline measurement is also 
required. Subjects will be included in the treatm ent group corresponding to the IP they actually 
received.
5.4.4. Apremilast Subjects as Randomized Population
The efficacy analysis during Weeks 12-104 will be based on the apremilast subjects as 
randomized population, which will include all subjects who are randomized (at Week 0) or re-
randomized (at Week 12) to an apremilast dose group and receive at least 1 dose of apremilast.
To assess change from baseline, a baseline value and at least 1 post-baseline value are also required. Subjects will be included in the a premilast dose group to which they were randomized 
or re-randomized.
5.4.5. Apremilast Subjects as Treated Population
The safety analysis for an apremilast-exposure period will be based on the apremilast subjects as 
treated population, which will include all subjects who are randomized (at Week 0) or assigned 
(at Week 12) to an apremilast dose group, and receive at least 1 dose of apremilast. At least 1 post-baseline assessment is required for inclusion in the analysis of each specific laboratory, vital 
sign, weight, or ECG parameter. To assess change from baseline, a baseline measurement is also 
required. Subjects will be included in the apremilast dose group corresponding to the apremilast dose they actually received.
&(/*(1y1(35235,(7$5<,1)250$7,21ululatatioionn, , 
of IP. of IP. AtAtll
ific fic laboratoborat
e measureme measurem
g to the IP to the I
n the apremthe aprem
who are ranho are ra
and receivand receiv
nd at least nd at least 
ilast dose gilast dose
eated Popuated Pop
st--exposureexposur
clclude allude all  susull
t dose groupdose grou
s required frequired 
arameterarameter . . T
ill be includll be inclu
received.received.
Apremilast (CC-10004)
Statistical Analysis Plan. Protocol CC- 10004-UC-001 Celgene 
Confidential and Propri etary 236. SUBJECT DISPOSITION
The number of subjects screened, the numbers and percentages of subjects randomized and not 
randomized, a nd of the eligibility criteria f ailed will be summarized based on all subjects 
screened.
The number and percentage of subjects included in the analysis populations will be summarized 
based on all subjects randomized.
Subject disposition (entered, completed, discontinued, along with primary reason for 
discontinuation) will be summarized based on all subjects randomized, unless otherwise specified below, for
!Weeks 0-12
!Weeks 0-52
!Weeks 12-52 (based on subjects who complete Week 12)
!Weeks 52-104 (based on subjects who enter the Extension Phase)
!Post-treatment observational follow-up phase (entered and completed only) within each 
of the above periods (based on subjects who enter the respective period)
The definitions of entry and completion in the above disposition summaries are given in Table 2 .
Table 2: Definitions of Entry and Completion in Disposition Summaries
Disposition 
CategoryWeeks 0-12 Weeks 0-52 Weeks 12-52 Weeks 52-104 Follow-up Phase
Entered Randomized Randomized Completed 
Week 12/Visit 
6Completed 
Week 52/Visit 
11 and 
indicated continuation 
into Extension 
Phase in eCRF Indicated continuation into 
Follow-up Phase in eCRF 
and had data after the last 
non-follow-up visit (Week 104/Visit 14 or ET visit, 
excluding any unscheduled 
visits associated with Week 104/Visit 14 and ET visit)
Completed Completed 
Week 12/Visit 6Completed 
Week 52/Visit 11Completed 
Week 52/Visit 11Completed 
Week104/Visit 14Completed the follow-up 
visit
A listing of discontinued subjects with r eason for discontinuation  will be provided.
The number and percentage of subjects by region , country, and site will be provided based on all 
subjects randomized.
&(/*(1(35235,(7$5<,1)250$7,21hase)ase)
nd completnd complet
e respectrespect iveiv
positositioion sumn s
on inn in DispoDisp
eks 12eks 12 -52-52(7777
CompleteComplete
Week Week
665,
(23
pleted pleted 
Week 12/Visiteek 12/Visit
661(((
****((
of discontdiscon
number annumber an
ubjects randubjects rand
Apremilast (CC-10004)
Statistical Analysis Plan. Protocol CC- 10004-UC-001 Celgene 
Confidential and Propri etary 247. PROTOCOL DEVIATIONS/VIOLATIONS
Protocol violations and deviations will be summarized for the Screening Phase and Weeks 0-12
using the ITT population, fo r Weeks 12-52 for sub jects who complete Week 12, and for Weeks 
52-104 for subjects who enter the Extension Phase.
A listing of all protocol violations and de viations in the st udy will be  provided.
&(/*(1(35235,(7$5<,1)250$7,21
Apremilast (CC-10004)
Statistical Analysis Plan. Protocol CC- 10004-UC-001 Celgene 
Confidential and Propri etary 258. DEMOGRAPHICS AND BASELINE CHARACTERISTICS
Demographics and baseline characteristics will be summarized descriptively using the ITT 
population. Th e comparability of the treatment groups for each relevant characteristic will be 
assessed descriptively in table format; no statistical hypothesis tests will be performed on these 
characteristics. Subject data listings will be p rovided.
8.1. Demographics and Baseline Characteristics
The following characteristics will be summarized as continuous variables:
!Age (years)
!Baseline body weight (kg)
!Baseline body mass index (BMI; kg/m2)
The following characteristics will be summarized as categorical variables:
!Age (< 65, ‚â• 65 years; < 40, 40 ‚Äì < 65, 65 ‚Äì < 75, 75 ‚Äì < 85, ‚â• 85 years)
!Sex (male, female)
!Race (American Indian or Alaska Native, Asian, Black or African American, Native 
Hawaiian or Other Pacific Islander, White, other, not collected or reported)
!Ethnicity (Hispanic or Latino, not Hispanic or Latino, unknown)
!Region (North America, Western Europe, Eastern Europe/Russia, Australia/New 
Zealand)
!Baseline body weight (< 55, 55 ‚Äì < 70, 70 ‚Äì < 85, 85 ‚Äì < 100, ‚â• 100 kg)
!Baseline BMI (< 18.5, 18.5 ‚Äì < 25, 25 ‚Äì < 30, 30 ‚Äì < 35, 35 ‚Äì < 40, and ‚àÄ40 kg/m2)
!Alcoholic beverages (yes [< 1 drink per week, 1 ‚Äì 14 drinks per week, > 14 drinks per 
week], no)
!Tobacco history (never smoked, past smoker, current smoker) 
Age will be calculated as (date of informed consent ‚Äì date of birth + 1) / 365.25 when the full 
date of birth is collected; otherwise, the age recorded will be used.
8.2. Baseline Disease Characteristics
The following baseline disease characteristics will be summarized as continuous variables:
!Duration of UC (years)
!Screening TMS
!Baseline TMS
!Baseline PMS
!Baseline MMS&(/*(1(35235,(7$5<,1)250$7,21s:
‚â• 85 years‚â• 85 years
Black Black or o
not not colleccolle
or Latino,or Latino, u
Europeurope ,EaE
< 70, 70 < 70, 70
‚Äì < 25, 25 ‚Äì< 25, 25
s s [< [< 11drindrin
(never smnever sm o
ed as (date d as (date
llected; othllected; oth
Baseline DBaseline D
oowing baseng bas
!!DuratiDurati
!ScSc
!
Apremilast (CC-10004)
Statistical Analysis Plan. Protocol CC- 10004-UC-001 Celgene 
Confidential and Propri etary 26!Baseline SFS
!Baseline RBS
!Baseline PGA subscore
!Baseline endoscopy subscore
!Baseline SF-12v2 Physical Component Summary (PCS) score
!Baseline SF-12v2 Mental Component Summary (MCS) score
The following baseline disease characteristics will be summarized as categorical variables:
!Duration of UC (< 2, 2 ‚Äì < 5, 5 ‚Äì < 10, ‚â• 10 years)
!Disease localization (Rectum and sigmoid colon only, left side of colon)
!Baseline extraintestinal manifestations (yes [peripheral arthropathy, axial arthropathies, 
pyoderma gangrenosum, erythema nodosum, ep iscleritis, uveitis, primary sclerosing 
cholangitis, other], no)
!Therapeutic failure with or intolerance to UC medications (yes [never responded, loss of 
response, partial response, intolerance], no)
!Therapeutic failure with or intolerance to oral aminosalicylates (yes [never responded, 
loss of response, partial response, intolerance], no)
!Therapeutic failure with or intolerance to budesonide (yes [never responded, loss of 
response, partial response, intolerance], no)
!Therapeutic failure with or intolerance to systemic corticosteroids (yes [never responded, 
loss of response, partial response, intolerance], no)
!Therapeutic failure with or intoleran ce to immunosuppressants (yes [never responded, 
loss of response, partial response, intolerance], no)
!Contraindication to UC medications (yes [oral aminosalicylates, budesonide, systemic 
corticosteroids, immunosuppressants], no)
!Concomitant use of oral corticosteroids (as randomized) (yes, no)
!Concomitant use of oral corticosteroids (per clinical database) (yes, no)
!Previous exposure to immunosuppressants (as randomized) (yes, no)
!Previous exposure to immunosuppressants (per clinical database) (yes, no)
!Screening TMS (< 6, 6 ‚Äì 8, 9 ‚Äì 11, 12)
!Baseline TMS (< 6, 6 ‚Äì 8, 9 ‚Äì 11, 12)
!Baseline endoscopy subscore (0 ‚Äì 1, 2, 3)&(/*(1(35235,(7$5<,1)250$7,21cal variablecal variabl
e of colon)e of colon)
rthropathyropathy
iis, uveits, uveit is, 
medicationsmedications
o o oral aminoral am
ololeranceerance ], n]n
rance torance to bu
ololeranceeranc ], n
r intoleranr intoleran
al responsel response
e with with or inor in
e, partie, part al rere
atatioion to Un to U
eroieroids, immds, imm
comitant ucomitant u
ConcomitaConcomita
!!PrevioPrevio
!PrPr
Apremilast (CC-10004)
Statistical Analysis Plan. Protocol CC- 10004-UC-001 Celgene 
Confidential and Propri etary 27Duration of UC will be calculated as (date of informed consent ‚Äì date of diagnosis + 1) / 365.25.
8.3. Medical History
Medical history will be coded according to the Medical Dictionary for Regulatory Activities 
(MedDRA), and summarized based on the ITT population by system organ class (SOC) and preferred term (PT), with SOCs sorted in the standard international order and PTs within each 
SOC in descending order of frequency, and by PT only in descending order of frequency.
8.4. Prior Medications/Procedures
Prior medications are defined as medications with  a start date before the date of the first dose of 
IP in the study (whether or not the end date is before the date of the first dose of IP). Prior 
medications that continue on or after the date of the first dose of IP will be also reported as 
concomitant medications. The Anatomical Therapeutical Chemical (ATC) coding scheme of the World Health Organization Drug Dictionary (WHODD) will be used to group medications into 
relevant categories. Prior medications will be  summarized based on the ITT population by ATC2
level and standardized medication name, with ATC2 levels and standardized medication names within each ATC2 level sorted in descending order of frequency.
Prior procedures are similarly defined. Prior procedures will be coded according to the 
MedDRA, and summarized based on the ITT population by SOC and PT, with SOCs sorted in the standard international order and PTs with in each SOC in descending order of frequency.
&(/*(1(35235,(7$5<,1)250$7,21nd 
n each ach
ency.ency.
te of the te of the firfi
t dose of IPose of
will be also ill be also
al (ATC) co(ATC) c
e used to grused 
ased on theased on the
ls and stanls and stan
frequency.frequency.
dures will dures will 
opulatpulat ioionnb
hin each SOhin each SO
Apremilast (CC-10004)
Statistical Analysis Plan. Protocol CC- 10004-UC-001 Celgene 
Confidential and Propri etary 289. EXTENT OF EXPOSURE TO INVESTIGATIONAL PRODUCT
9.1. Treatment Duration
Treatment duration will be summarized for the Weeks 0-12 placebo-controlled phase using the 
safety population, for the Weeks 0-52 and Weeks 0-104 a premilast-exposure periods using the 
apremilast subjects as treated population, and for the Weeks 52-104 apremilast-exposure period 
for subjects who receive at least 1 dose of apremilast after Week 52. 
Treatment duration (in weeks) is calculated as (the date of the last dose of IP in the period ‚Äì the 
date of the first dose of IP in the period + 1) / 7 and rounded to one decimal place. The date of 
the last dose of IP in the Weeks 0-12 placebo-cont rolled phase is defined as the date before IP 
dispensing at Week 12. The date of the last dose of IP in the Weeks 0-52 apremilast-exposure 
period and the date of the first dose of IP in the Weeks 52-104 apremilast-exposure period are 
defined as the date before and the date of, respectively, IP dispensing at Week 52.
Treatment duration will be summarized as a conti nuous variable, and as a categorical variable 
with the following exposure intervals: 
!Weeks 0-12 p lacebo-contro lled phase: ‚â§ 4, > 4 ‚Äì 8, > 8 ‚Äì 12, > 12 weeks
!Weeks 0-52 apremilast-exposure period: ‚â§ 4, > 4 ‚Äì 8, > 8 ‚Äì 12, > 12 ‚Äì 20, > 20 ‚Äì 28, > 28 
‚Äì 36, > 36 ‚Äì 44, > 44 ‚Äì 52, and > 52 weeks
!Weeks 0-104 apremilast-exposure period: ‚â§ 4, > 4 ‚Äì 8, > 8 ‚Äì 12, > 12 ‚Äì 20, > 20 ‚Äì 28, 
> 28 ‚Äì 36, > 36 ‚Äì 44, > 44 ‚Äì 52, > 52 ‚Äì 68, > 68 ‚Äì 86, > 86 ‚Äì 104, > 104 weeks
!Weeks 52-104 apremilast-exposure period (intervals denote the number of weeks relative 
to the date of the first dose of IP in the Weeks 52-104 apremilast-exposure period as defined above): ‚â§ 16, > 16 ‚Äì 34, > 34 ‚Äì 52, > 52 weeks
A subject data listing of study drug records will be provided. 
9.2. Treatment Compliance
As part of the routine recording of the amount of IP taken by each subject, the numbers of tablets 
dispensed and returned will be recorded at each visit. These records will be used to calculate 
treatment compliance. Treatment compliance will be summarized for the Weeks 0-12 placebo-
controlled phase using the ITT population, for Weeks 12-52 for subjects who receive at least 1 
dose of apremilast after Week 12 (defined as the date of the last dose of apremilast in the study
no earlier than the date of IP dispensing at Week 12), and for Weeks 52-104 for subjects who receive at least 1 dose of apremilast aft er Week 52.
The compliance rate (%) for each subject will be computed as 100 times the total number of 
tablets taken (the total number of tablets dispensed minus the total number of tablets returned) over the period divided by the intended total number of tablets that should have been taken over 
the same period (defined by the first and last IP dose dates in the period). The date of the last 
dose of IP in the Weeks 0-12 placebo-controlled phase and the date of the first dose of IP in Weeks 12-52 are defined as the date before and the date of, respectively, IP dispensing at Week &(/*(1(35235,(7$5<,1)250$7,21‚Äì‚Äìthhe e 
date of date of 
before IP before IP
lastlast--exposuexposu
osure perioosure peri
eek 52.eek 52.
as a categors a catego
12,12,> 12 w
8, > 8 , > 8 ‚Äì‚Äì121
4, > 4 4, > 4 ‚Äì8, 8
8, > 68 , > 68 ‚Äì8686
eriod (intereriod (inte
the Weekthe Week
, > 34 > 34 ‚Äì5252
g records wecords w
mpliancempliance
cording of tcording o
d will be rewill be
nce. Treatmnce. Treatm
using the using the 
milastmilast aftaftere
than the dahan the da
at least 1 dat least 1 d
e compliancomplian
tablablets takeets take
over thever th
s
Apremilast (CC-10004)
Statistical Analysis Plan. Protocol CC- 10004-UC-001 Celgene 
Confidential and Propri etary 2912. The date of the last dose of IP in Weeks 12-52 and the date of the first dose of IP in Weeks 
52-104 are defined as the date before and the date of, respectively, IP dispensing at Week 52.
Treatment compliance rate will be summarized as a continuous variable, and as a categorical 
variable with the following categories:  < 75%, 75% ‚Äì 120%, and > 120%.
A subject data listing of drug accountab ility records will be provided.
Apremilast (CC-10004)
Statistical Analysis Plan. Protocol CC- 10004-UC-001 Celgene 
Confidential and Propri etary 3010. CONCOMITANT MEDICATIONS AND PROCEDURES
Concomitant medications and procedures will be summarized for the Weeks 0-12 placebo-
controlled phase using the safety population, for the Weeks 0-52 and Weeks 0-104 apremilast-
exposure periods using the apremilast subjects as treated population, and for the Weeks 52-104 
apremilast-exposure period for subjects who receive at least 1 dose of apremilast after Week 52.
10.1. Concomitant Medications
A concomitant medication in each of the a bove periods is defined as a non-study med ication 
with any amount taken during the period as defined in Section 5.2.
The ATC coding scheme of the WHODD will be used to group medications into relevant 
categories. Concomitant medications will be summarized by ATC2 level and standardized 
medication name, with ATC2 levels and standardized medication names within each ATC2 level 
sorted in descending order of frequency.
10.2. Concomitant Procedures
Concomitant procedures are defined similarly to concomitant medications. Concomitant procedures will be coded according to the MedDRA, and summarized by SOC and PT, with SOCs sorted in the standard international order and PTs within each SOC in descending order of 
frequency.
&(/*(1(35235,(7$5<,1)250$7,21on on
ellevant evant 
andardizedandardiz
hin each hin each AA
medicatedica ions
mmarized bmmarized 
within each within each 
Apremilast (CC-10004)
Statistical Analysis Plan. Protocol CC- 10004-UC-001 Celgene 
Confidential and Propri etary 3111. EFFICACY ANALYSIS
11.1. Multiplicity
Formal statistical tests, conducted at a 2-sided significance level of 0.1, are planned between 
APR 40 BID and placebo and between APR 30 BID and placebo for the primary efficacy 
endpoint. To control the family-wise Type 1 error rate at the 0.1 level, these 2 formal statist ical 
tests will be carried out by using a fixed sequence testing procedure, with the comparison between APR 40 BID and placebo tested first. The comparison between APR 30 BID and 
placebo will be tested only if the comparison between APR 40 BID and placebo is statist ically 
significant. If any of the 2 apremilast dose groups is discontinued prior to the end of the study, the treatment comparison will be conducted for the comparison between the retained apremilast 
dose and placebo at a 2-sided significance level of 0.1.
 
For formal statistical tests that are planned but not performed as a result of the aforementioned 
multiplicity adjustment str ategy, as well as for any other comparisons that are not subjected to 
multiplicity adjustment , nominal 2-sided p-values (without adjustment for multip licity) will be 
provided as a measure of the strength of asso ciation between the endpoint and the treatment 
effect rather than formal tests of hypotheses.
11.2. Missing Data Handling
11.2.1. Treatment Failures
Subjects who have (1) protocol-prohibited initiation or dose increase of concomitant UC 
medications, or (2) a colectomy (partial or total) or an ostomy will be considered treatment 
failures after the date of the event. Use of antidiarrheals or dose increase of oral corticosteroids 
back to the baseline dose for subjects undergoing corticosteroid tapering will not be considered a treatment failure.
Efficacy data after the date of treatment failure will be considered missing. Of note, for efficacy 
 analyses, the data after the date of treatment failure will be set to missing prior to 
the assignments of analysis time points as described in Section 5.3.1 .
11.2.2. Binary Efficacy Endpoints
11.2.2.1. Primary Approach for Analysis
For binary efficacy endpoints, the primary approach to handling missing data will be 
nonresponder imputation (NRI), where subjects who have insufficient data for response determination for the time point under consideration will be considered nonresponders for that 
time point. Insufficient data, including missing data at baseline (if the binary endpoint assesses 
change from baseline) or a post-baseline time point, will be determined after the handling of time points as described in Sections 5.3. &(/*(1(35235,(7$5<,1)esultlt of ofthe the ff
isons that ans that 
justjustmementnt f
en the endpn the end
ed inited init iatiatio
al or totalal or tot )
Use of antse of ant i
bjects undebjects unde
ate of treatmate of tre
eses, the data, the da
analysanalys is tis timim
nary Efficnary Effic
PrimarPrimar
binarybinary efficeffi
nonrespondeonrespond
determindetermin)250$7,21stically cally 
the study, the study, 
ned apremiled apremi
me pme p1)2
Apremilast (CC-10004)
Statistical Analysis Plan. Protocol CC- 10004-UC-001 Celgene 
Confidential and Propri etary 3211.2.2.2. Sensitivity Analyses
Sensitivity analyses using different missing data handling approaches (data as observed [DAO] 
and last observation carried forward [LOCF]) will be performed for the primary efficacy 
endpoint (clinical remission defined in the T MS) and the first secondary efficacy endpoint 
(clinical response defined in the TMS).
In the DAO analyses, only subjects with suff icient data for response determination at the time 
point under consideration will be included.
In the LOCF analyses, missing data at the time point under consideration will be imputed by the 
last post-baseline observation. For the TMS which consists of 4 individual subscores, the LOCF 
method will be applied to the individual subscores rather than directly to the TMS, and then the TMS will be calculated based on the observed or imputed subscores. Subjects who still have 
insufficient data for response determination at the time point under consideration despite the 
application of LOCF (eg, no post-baseline data) will be considered nonresponders for that time point.
11.2.2.3. Approach for Descriptive Summary
Binary endpoints by t ime point will also be summarized based on DAO, where only subjects 
with sufficient data for response determination at the time point under consideration will be 
included in the summary of that time point.
11.2.3. Continuous Efficacy Endpoints11.2.3.1. Primary Approach for Analysis
For continuous efficacy endpoints, the primar y missing data handling approach will be last 
observation carried forwarded (LOCF). For sub jects who initially  receive placebo and switch to 
an apremilast dose at Week 12 and subjects who initially receive APR 30 BID and switch to APR 40 BID at Week 12, the values on or before the date of IP dispensing at Week 12 will not 
be carried over beyond Week 12. For the TMS, PMS, and MMS, which are composite scores 
derived from individual subscores, the LOCF method will be applied to the individual subscoresrather than to the composite score.
11.2.3.2. Approach for Descriptive Summary
Continuous endpoints by time point will also be summarized based on DAO, where only subjects 
with sufficient data at the time point under consideration will be included in the summary of that 
time point.
11.3. Analysis of Primary Endpoint
11.3.1. Primary Analysis of Primary Endpoint
The primary objective of the study will be evaluated by testing the superiority of each of the 2 
apremilast doses over placebo with respect to the proportion of subjects achieving a clinical remission in the TMS, defined as a TMS of ‚â§ 2, with no individual subscore > 1, at Week 12 
based on the ITT population and the Cochran-Mantel-Haenszel (CMH) test stratified by the 
randomizatio n stratification f actors. Within-group proportions, 2-sided 95% CIs (based on the &(/*(1(35235,(7$5<,1)250$7,21ythe the
LOCF LOCF 
d then the then the 
stilstill lhave have 
n despite then despite th
ders for thaders for th
DAODA , whe wh
tt under con under
aryary missingmissingyy
or or subjects subjects
jects who iects who 
on or befoon or be
ForForththeeTMT
ores, the Lores, the L
e scorescore .
h for Descrh for Des
intints bys by titiyymm
data at thedata at th
Annall
11.3.1.1.3.1.
he prihe pr
Apremilast (CC-10004)
Statistical Analysis Plan. Protocol CC- 10004-UC-001 Celgene 
Confidential and Propri etary 33Wilson score method) fo r the within-group proportions, unstratified tr eatment differences in 
proportions, stratified treatment differences in proportions using the weighted average of the 
treatment differences across the strata with the CMH weights, stratified 2-sided 95% CIs (based 
on the stratified Newcombe method [ Yan, 2010 ]) for the treatment differences in proportions, 
and the 2-sided p-values from the CMH tests, will be provided. Missing data will be handled by 
the NRI approach.
11.3.2. Sensitivity Analyses of Primary Endpoint
The following sensitivity analyses will be performed for the primary endpoint: 1) using the PP 
population and the NRI method for missing data; 2) using DAO (Section 11.2.2.2 ); 3) using the 
ITT population and the LOCF method for missing data (Section 11.2.2.2) . The statistical 
methods adopted for the primary analysis will also be used for these sensitivity analyses.
11.4. Analyses of Secondary Efficacy Endpoints
The analyses of secondary efficacy endpoints will be performed identically to the primary analysis of the primary endpoint. In addition, the sensitivity analyses of the primary endpoint
will also be performed for the first secondary efficacy endpoint (clinical response defined in the 
TMS).
 
 
 
 
 
 
 
&(/*(1(35235,(7$5<,1)250$7,21PP PP 
ng the ng the 
al al 
yses.yses.
ly to the priy to the pr
f the primaf the prim
nical responcal respon
7$5(7$(75,(735,(352
3(31(
*(1/*(((/*&(&(&
Apremilast (CC-10004)
Statistical Analysis Plan. Protocol CC- 10004-UC-001 Celgene 
Confidential and Propri etary 34 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 &(/*(1(35235,(7$5<,1)250$7,210$50$50250)25)21)2
<, 1<, 15<$5<7$57,(7
35,(23552335235(31((1((1*(/*((/*&(&(&
Apremilast (CC-10004)
Statistical Analysis Plan. Protocol CC- 10004-UC-001 Celgene 
Confidential and Propri etary 35 
  
 
 
 
 
 
 
 
 
 
&(/*(1(35235,(7$5<,1)250$7,21,1)<, 15<,5<$5<
(7$
35,(2352335235
1(3(1((1*(
(/*&(&(/&(&(&
Apremilast (CC-10004)
Statistical Analysis Plan. Protocol CC- 10004-UC-001 Celgene 
Confidential and Propri etary 36 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
11.7. Assessing Study Center Effect and Treatment-by-center Interaction
This study is a multicenter study. The limited s ample size of the study relative to the number of 
study sites does not allow for a meaningful assessment of study center effect.&(/*(7.7. AssAs
This studyThis study
studytudy sisyy( 35235,(7$5<,1)250$7,217
0$7
)21)21)
$5<
(7$5,(35
523
(3 51(31((1*(1
Apremilast (CC-10004)
Statistical Analysis Plan. Protocol CC- 10004-UC-001 Celgene 
Confidential and Propri etary 3712. SAFETY ANALYSIS
Safety will be evaluated via descriptive statisti cs and point estimates. No inferential testing for 
statist ical signif icance will be performed.
The safety analyses will be based on the safe ty population for the Weeks 0-12 placebo-controlled 
phase, the apremilast subjects as treated population for the Weeks 0-52 and Weeks 0-104 apremilast-exposure periods, and subjects who receive at least 1 dose of apremilast after Week 
52 for the Weeks 52-104 apremilast-exposure period. The treatment groups presented for these 
analysis periods are described in Section 5.2.
12.1. Adverse Events
AEs will be coded according to the MedDRA. Unless otherwise specified, AEs will be 
summarized by SOC and PT, with SOCs sorted in the standard international order and PTs 
within each SOC in descending order of subject incidence.
For the analyses of AEs, the following point estimates are provided, unless otherwise specified:
!Subject incidence: Subject incidence (i.e., pe rcentage [%] used in a frequency summary) 
is defined as the number of subjects with the specific event divided by the number of subjects included in the analysis. Subjects with multiple occurrences of the specific event 
in the specific analysis period will be counted only once in the numerator.
!Exposure-adjusted incidence rate (EAIR) per 100 person-years: The EAIR per 100 
person-years is defined as 100 times the number of subjects with the specific event divided by the total exposure time (in years) to the event among subjects included in the 
analysis. Subjects with multiple occurrences of the specific event in the specific analysis 
period will be counted only once in the numerator. The exposure time for a subject without the specific event is the duration of the specific analysis period as described in 
Section 5.2, whereas the exposure time for a subject with the specific event is the 
duration of the specific analysis period up to the start date (inclusive) of the first occurrence of the specific event. The total exposure time in years is calculated by 
dividing the sum of exposure time in days over all subjects included in the analysis by 
365.25. The EAIR per 100 person-years is interpreted as the expected number of subjects with at least 1 occurrence of the specific event per 100 person-years of exposure to the 
event.
A subject data listing of all AEs (including tr eatment-emergent AEs [TEAEs] and non-TEAEs) 
will be provided.
12.1.1. Overall Summary of TEAEs
An overall summary of the following TEAE categories will be provided for the Weeks 0-12 
placebo-controlled phase, the Weeks 0-52, Weeks 0-104, and Weeks 52-104 apremilast-exposure 
periods:
!Any TEAE
!Any drug-related TEAE&(/*(1(35235,(7$5<,1)250$7,21ese se 
will be will be 
order and Porder and
unless othernless other
 used in a fsed in a f
vent vent dividediv
iple occurrple occu
ly once in ty once in
r 100 persor 100 pers
number of sumber of 
years) to thyears) to th
urrences ofurrences o
in the numin the nu
he durationhe durat
xposure timposure tim
analysis peanalysis pe
cific eventcific event
of exposureof exposure
AIR per 100AIR per 10
1 occurrenoccurren
ta listta list ing oing o ff
ovided.vided.
1.1. OveOv
An overall An overall 
plplaceboacebo
rio
Apremilast (CC-10004)
Statistical Analysis Plan. Protocol CC- 10004-UC-001 Celgene 
Confidential and Propri etary 38!Any severe TEAE 
!Any serious TEAE
!Any serious drug-related TEAE
!Any TEAE leading to drug interruption
!Any TEAE leading to drug withdrawal
!Any TEAE leading to death
In addition, the overall summary of TEAE categories will be provided by age category (< 65, ‚â• 
65), race (white, non-white) , and region (North America, Western Europe, Eastern 
Europe/Russia, Australia/New Zealand) for the Weeks 0-12 placebo-controlled phase and the 
Weeks 0-104 apremilast-exposure period.
12.1.2. All TEAEs
All TEAEs will be summarized by SOC and PT as well as by PT only (in descending order of 
subject incidence) for the Weeks 0-12 placebo-controlled phase, the Weeks 0-52, Weeks 0-104, 
and Weeks 52-104 apremilast-exposure periods.
All TEAEs by exposure interval will be summarized for the Weeks 0-12 placebo-controlled 
phase and the Weeks 0-104 apremilast-exposure period. The exposure intervals are ‚â§ 2, > 2 ‚Äì 4, 
> 4 ‚Äì 8, > 8 weeks for the Weeks 0-12 placebo-controlled phase, and ‚â§ 2, > 2 ‚Äì 4, > 4 ‚Äì 12, > 12 
‚Äì 20, > 20 ‚Äì 28, > 28 ‚Äì 36, > 36 ‚Äì 44, > 44 ‚Äì 52, > 52 ‚Äì 68, > 68 ‚Äì 86, > 86 weeks for the Weeks 
0-104 apremilast-exposure  period. Each subject is counted once in the numerator of a subject 
incidence or EAIR for each applicable specific TEAE in each exposure interval where an event starts. The denominator of a subject incidence is the number of subjects with the exposure time
reaching the lower bound of the particular exposure in terval, and the denominator of an EAIR is 
the sum of the exposure time during the exposure interval (up to the start date [inclusive] of the first occurrence of the specific event for each subject reporting the event in the interval) among
the same number of subjects as in the denominator of the corresponding subject incidence.
All TEAEs will be summarized by sex and concomitant use of oral corticosteroids for the Weeks 
0-12 placebo-controlled phase and the Weeks 0-104 apremilast-exposure period.
All TEAEs starting after the date of the last dose of IP and up to 28 days after the last dose of IP 
will be summarized for subjects who enter the observational follow-up phase during the Weeks 0-12 placebo-controlled phase and the Weeks 0-104 apremilast-exposure period. The EAIR will 
not be provided in this summary.
12.1.3. Common TEAEs
Any TEAEs with subject incidence ‚â• 5% (or another cutoff if justified) in any treatment group
and any non-serious TEAEs with subject incidence ‚â• 5% (or another cutoff if justified) in any 
treatment group will be summarized for the Weeks 0-12 placebo-controlled phase and the Weeks 
0-104 apremilast-e xposure period.
Onset day and duration will be summarized fo r any TEAEs with subject incidence ‚â• 5% (or 
another cutoff if justified) in any treatment group for the Weeks 0-12 placebo-controlled phase 
and the Weeks 0-104 apremilast-exposure period. Multiple occurrences of a specific event for &(/*(1(35235,(7$5<,1)250$7,2165, 65, ‚â• ‚â• 
e and e and ththe e
n descendindesce
Weeks 0Weeks 0 --5252
eeks 0eeks 0 -12 
e exposureexposure
d phasephase , an, 
‚Äì‚Äì68, > 68 68, > 68
counted oncounted on
TEAE in eaTEAE in 
e is the nume is the num
exposure iexposure i
e exposure exposure
fofor reach sueach
n the denomn the deno
ed by sex ed by sex 
hase and se an thth
ter the dateter the da
d for subjecd for subjec
ntntrolled phrolled ph
ded in this sed in this s
CommComm
yTEAEs wTEAEs w
nd nd aany ny nono
treatmreatm enen
10404
Apremilast (CC-10004)
Statistical Analysis Plan. Protocol CC- 10004-UC-001 Celgene 
Confidential and Propri etary 39the same subject will all be counted in the summaries of onset day and duration. For subjects 
who initially receive placebo and switch to an apremilast dose at Week 12, AEs with start dates 
in the placebo-controlled phase and end dates  in the apremilast-exposure period will be
summarized as ongoing for the summary of durati on in the placebo-controlled phase, whereas for 
all other subjects, the actual AE end dates regardless of being in the placebo-controlled phase or 
apremilast-exposure period w ill be used for calcu lating duration. Duration will not be calculated 
for AEs reported as ongoing.
12.1.4. Drug-related TEAEs
Drug-related TEAEs will be summarized for the Weeks 0-12 placebo-controlled phase, the 
Weeks 0-52, Weeks 0-104, and Weeks 52- 104 apremilast-exposure periods.
12.1.5. TEAEs by Maximum Severity
All TEAEs will be summarized by maximum severity (mild, moderate, severe, and, if needed, 
missing) for the Weeks 0-12 placebo-controlled phase, the Weeks 0-52, Weeks 0-104, and 
Weeks 52-104 apremilast-exposure periods. If a subject reports multiple occurrences of a 
specific event within a specific analysis period, the subject will be counted only once by the maximum severity. If the severity is missing for one or more of the occurrences, the maximum 
severity of the remaining occurrences will be used. If the severity is missing for all of the 
occurrences, the subject will be counted only once in the ‚Äúmissing‚Äù category of severity.
12.1.6. Serious TEAEs
Serious TEAEs will be summarized for the Weeks 0-12 placebo-controlled phase, the Weeks 0-
52, Weeks 0-104, and Weeks 52-104 apremilast-exposure periods.
Serious TEAEs will also be summarized by sex and concomitant use of oral corticosteroids for 
the Weeks 0-12 placebo-controlled phase and the Weeks 0-104 apremilast-exposure period.
A subject data listing of all serious AEs (both TEAEs and non-TEAEs) will be provided.
12.1.7. TEAEs Leading to Drug Interruption and Leading to Drug Withdrawal
TEAEs leading to drug interruption will be summarized for the Weeks 0-12 placebo-controlled 
phase, the Weeks 0-52 and Weeks 0-104 apremilast-exposure periods.
TEAEs leading to drug withdrawal will be summarized for the Weeks 0-12 placebo-controlled 
phase, the Weeks 0-52, Weeks 0-104, and Week s 52-104 apremilast- exposure periods.
TEAEs leading to drug withdrawal will also be summarized by sex and concomitant use of oral 
corticosteroids for the Weeks 0-12 placebo-controlled phase and the Weeks 0-104 apremilast-
exposure period.
A subject data listing of TEAEs leading to drug withdrawal will be provided.
12.1.8. Deaths
TEAEs leading to death will be summarized for the Weeks 0-12 placebo-controlled phase, the 
Weeks 0-52 and Weeks 0-104 apremilast-exposure periods. A subject data listing of all deaths 
will be provided.&(/*(1(35235,(7$5<,1)250$7,21e e 
e, and, if ne, and, if n
Weeks 0Weeks 0 -104104
e occurrence occurre
ounted onlyunted only
he occurrenoccurren
ritrity y is ismissm
missing‚Äù catissing‚Äù ca
00-12 pl12 pl acea
st--exposureexposur
y sex and csex and c
se and e and ththe eW
AEs (both TAEs (both
o Drug Into Drug In
terruption ruptio w
and Weeksand Week
drug withdrdrug withdr
s 0s 0-52, We52, W
ing to druging to drug
roiidsdfofor thr th
ure periodure period
subject datsubject dat
2.1.8.2.1.8.
Apremilast (CC-10004)
Statistical Analysis Plan. Protocol CC- 10004-UC-001 Celgene 
Confidential and Propri etary 4012.2. Clinical Laboratory Evaluations
The following protocol-specified hematologic and serum chemistry parameters from the central 
laboratory will be summarized:
!Hematology: complete blood count (red blood cell [RBC] count, hemoglobin, hematocrit, 
white blood cell [WBC] count and differential, absolute WBC counts, platelet count)
!Serum chemistries: total protein, al bumin, calcium, phosphorous, glucose, total 
cholesterol, high-density lipoprotein cholesterol (HDL), low-density lipoprotein 
cholesterol (LDL), triglycerides, uric aci d, total bilirubin, alkaline phosphatase, aspartate 
aminotransferase (AST)/serum glutamic-oxaloacetic transaminase (SGOT), alanine aminotransferase (ALT)/serum glutamic -pyruvic transaminase (SGPT), sodium, 
potassium, chloride, carbon dioxide, blood urea nitrogen (BUN), creatinine, lactate 
dehydrogenase (LDH), magnesium
For the above hematologic and serum chemistr y parameters, summary st atistics of observed 
values and changes from baseline will be provided by time point (including the end of period and 
the post-treatment observational follow-up visit) for the Weeks 0-12 placebo-controlled phase, the Weeks 0-52 and Weeks 0-104 apremilast-exposure periods.  Frequency summaries (shift 
tables) of shifts from baseline to post-baseline time points (including shifts to the end of period 
value and to the worst value) by category of lo w/normal/high/both low and high (the last 
category for the shift to the worst value only) will be provided for the Weeks 0-12 placebo-
controlled phase, the Weeks 0-52 and Weeks 0-104 apremilast-exposure periods.
Frequency summaries of the shift from baseline to the worst value by folds of ULN (<= 1xULN, 
> 1 to 2xULN, > 2 to 3xULN, > 3 to 5xULN, > 5 to 8xULN, > 8xULN) will be provided for 
ALT, AST, total bilirubin, and alkaline phosph atase for the Weeks 0-12 placebo-controlled 
phase, the Weeks 0-52 and Weeks 0-104 apremilast-exposure periods.
Summaries of laboratory marked abnormalities as defined in Section 17.1 will be provided for 
the Weeks 0-12 placebo-controlled phase, the Weeks 0-52 and Weeks 0-104 apremilast-exposure 
periods. Subject incidence for each abnormality will be calculated based on subjects with a baseline value and at least 1 post-baseline value in the period under consideration for criteria 
requiring baseline, or subjects with at least 1 post-baseline value in the period under 
consideration for criteria not requiring bas eline. Separate summaries of laboratory marked 
abnormalities will also be  presented by normal baseline and abnormal baseline. For the purpose 
of these summaries, abnormal (normal) baseline is defined as a baseline value that is low (normal 
or high) for criteria concerning low values and as a baseline value that is high (normal or low) for criteria conce rning high values; both low and high are r elative to the labora tory normal range.
A subject data listing including all values of a subject‚Äôs laboratory parameter(s) that have any 
marked abnormality will be provided. A subject data listing of all laboratory data (including urinalysis) will be provided.
12.3. Vital Signs and Body Weight
For vital signs and body weight, summary sta tistics of observed values and changes from 
baseline (also percent change from baseline for body weight) will be provided by time point 
(including the end of period and the post-treatment observational follow-up visit) for the Weeks &(/*(1(35235,(7$5<,1)250$7,21artate tate 
ne e 
m, 
, lactate , lactate 
stticics of obseof obs
ng the end ng the 
placeboacebo --concon
equency suequency s
uding shiftuding shift ss
/both l/both l ow aow
dededfofor thert h
emilastemilast --expex
the worst vthe worst v
5 to 8xULN5 to 8xULN
phatasephatase foforr
premilastpremilast -
rmmalialititiiies a
phase, hase, ththee
ch abnormch abnorm
postpost--baselinbaselin
ctts wis withtii atah
a not requia not requ i
so be preseo be pres
es, es, abnormabnorm
erieria concea conc
concerning oncerning 
ct data listct data list i
ed abnormed abnorm
inalysis) winalysis) w
2.3.2.3.
Apremilast (CC-10004)
Statistical Analysis Plan. Protocol CC- 10004-UC-001 Celgene 
Confidential and Propri etary 410-12 placebo-controlled phase, the Weeks 0-52 and Weeks 0-104 apremilas t-exposure periods.
Frequency summaries (shift tables) of shifts from  baseline to post-baseline time points (including 
shifts to the end of period value and to the worst value) by category of low/normal/high/both low 
and high (the last category for the shift to the worst value only) will be provided for pulse, 
systolic and diastolic blood pressures (SBP and DBP) for the Weeks 0-12 placebo-controlled 
phase, the Weeks 0-52 and Weeks 0-104 apremilast-exposure periods. The normal ranges are 
defined as: 60 ‚Äì 100 beats/minute for pulse, 90 ‚Äì 140 mmHg for systolic blood pressure, and 60 ‚Äì 90 mmHg for diastolic blood pressure.
Frequency summaries of change and percent cha nge in body weight from baseline to the end of 
the respective analysis period for all subjects with a baseline value and at least 1 post-baseline value, as well as by baseline BMI category (< 18.5, 18.5 to < 25, 25 to < 30, 30 to < 35, 35 to 
< 40, and ‚àÄ40 kg/m
2) and by baseline weight category (< 70, ‚àÄ70 to < 85, ‚àÄ85 to < 100, and ‚àÄ
100 kg) w ill be provided for the Weeks 0-12 placebo-controlled phase, the Weeks 0-52 and 
Weeks 0-104 apremilast-exposure periods. The categories of weight change (kg) and percent 
change (%) are < -20, -20 to < -10, -10 to < -5, -5 to < 0, 0, > 0 to 5, > 5 to 10, > 10 to 20, and > 
20. The end of period value is the last post-baseline value in the respective analysis period (excluding the value obtained at the post-treatment observational follow-up visit, if applicable).
A subject data listing of all vital signs and body wei ght will be provided, with subjects with body 
weight loss of ‚àÄ7.5% from baseline flagged.
12.4. Electrocardiogram
Frequency summaries (shift tables) of the shift from baseline to the end of period in investigator 
clinical interpretation of ECG (normal; abnormal, not clinically significant; and abnormal, 
clinically significant) w ill be provided for the Weeks 0-12 placebo-controlled phase, the Weeks 
0-52 and Weeks 0-104 apremilast-exposure periods.
A subject data listing including all of a subject‚Äôs ECG interpretations will be provided for 
subjects who have any clinically significant abnormal interpretation by the investigator.
&(/*(1(35235,(7$5<,1)250$7,21d of of 
eline line 
5, 35 , 35 to to 
< 100, and< 100, and
ks 0ks 0-52 and52 and
kg) and pekg) and pe
o 10, > 10 t10, > 10 t
ive analysianaly
owow-up visiup vis
provirovided, ww
m baseline tm baseline 
l, not clinic, not clinic
Weeks 0Weeks 0
e periodse periods
a subject‚Äôs a subject‚Äôs 
gnificant abnificant a
Apremilast (CC-10004)
Statistical Analysis Plan. Protocol CC- 10004-UC-001 Celgene 
Confidential and Propri etary 42 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 &(/*(1(35235,(7$5<,1)250$7,21$$7
50$25025
1),1)<, 15<$5<$57$5(7$,5,(
23552
(3 51((1((1*(
(/*&(/&(&(&
Apremilast (CC-10004)
Statistical Analysis Plan. Protocol CC- 10004-UC-001 Celgene 
Confidential and Propri etary 43 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
&(/*(1(35235,(7$5<,1)250$7,2100$50$25025)21)2,1)<, 1<,5<
7$5(7$,(75,(35,352352335235(3 5(31((1(*(1
Apremilast (CC-10004)
Statistical Analysis Plan. Protocol CC- 10004-UC-001 Celgene 
Confidential and Propri etary 44 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 5235,(7$5<,1)250$7,21$0$50250)21)21),1<, 15<$5<7$5(7$5,(735,(23
35235(3
&(/*(1(
Apremilast (CC-10004)
Statistical Analysis Plan. Protocol CC- 10004-UC-001 Celgene 
Confidential and Propri etary 45&(/*(1(35235,(7$5<,1)250$7,215235,(7$5<,1)250$7,2
Apremilast (CC-10004)
Statistical Analysis Plan. Protocol CC- 10004-UC-001 Celgene 
Confidential and Propri etary 4615. CHANGES TO THE STATISTICAL ANALYSES SECTION OF 
THE PROTOCOL
Not applicable.
&(/*(1(35235,(7$5<,1)250$7,21
Apremilast (CC-10004)
Statistical Analysis Plan. Protocol CC- 10004-UC-001 Celgene 
Confidential and Propri etary 4716. REFERENCES
Yan X, Su XG. Stratified Wilson and Newcom be confidence interv als for mult iple binomial 
proportions. Statistics in Biopharmaceutical Research 2010;2:329-335.
&(/*(1(35235,(7$5<,1)250$7,21
Apremilast (CC-10004)
Statistical Analysis Plan. Protocol CC- 10004-UC-001 Celgene 
Confidential and Propri etary 4817. APPENDICES
17.1. Laboratory Marked Abnormalities Criteria
Table 5: Laboratory Marked Abnormalities Criteria
Category / Analyte SI Units Criteria 
Chemistry
   Alanine Aminotransferase (SGPT) U/L > 3 xULN  
   Albumin Kg/m3< 25
   Alkaline Phosphatase U/L > 400  
   Aspartate Aminotransferase (SGOT) U/L > 3 x ULN  
   Total Bilirubin Œºmol/L > 1.8 x ULN  
   Blood Urea Nitrogen mmol/L > 15
  Calcium mmol/L< 1.8
> 3.0
   Creatinine Œºmol/L > 1.7 x ULN 
   Glucose mmol/L< 2.8
> 13.9
   Lactate Dehydrogenase U/L > 3 x ULN
   Magnesium mmol/L > 1.2
   Phosphate mmol/L< 0.64
> 1.60
   Potassium mmol/L< 3.0
> 5.5
   Sodium mmol/L< 130
> 150
   Triglycerides mmol/L > 3.4
   Urate Œºmol/L Male: > 590; Female: > 480
Hematology
   Hemoglobin g/LMale: < 105; Female: < 85 
Male: > 185; Female: > 170
   Leukocytes 10^9/L < 1.5
   Lymphocytes 10^9/L < 0.8
   Neutrophils 10^9/L < 1.0
   Platelets 10^9/L< 75
> 600
&(/*(1(35235,(7$5<,1)250$7,21$7$$7$70$$$
505025)21)ULN UL,1
88
> 13.913.9<
$5$> 3 x > 3 x$$$57$/L/L >7$7$7$7$
mmol/Lmol/L(7777
mmol/mm5,323333
52353(31(cytescytes(1 rophilsphils*( PlateletsPlatele/*(/
Apremilast (CC-10004)
Statistical Analysis Plan. Protocol CC- 10004-UC-001 Celgene 
Confidential and Propri etary 49$7,21
&(/*(1(35235,(7$5<,1)250$7
Apremilast (CC-10004)
Statistical Analysis Plan. Protocol CC- 10004-UC-001 Celgene 
Confidential and Propri etary 50